TABLE 3.
Characteristics of patients with and without COVID-19 after vaccination
| COVID-19 (n = 37) | Without COVID-19 (n = 189) | p value | |
|---|---|---|---|
| Age (years) | 55 ± 13 | 58 ± 11 | .192 |
| Gender (male) | 20 (54) | 123 (65) | .278 |
| Time posttransplant (months) | 34 ± 27 | 99 ± 78 | <.001 |
| Previous transplantation | 4 (11) | 17 (9) | .969 |
| Cause of end stage renal disease | .231 | ||
| Chronic glomerulonephritis | 22 (59) | 89 (47) | |
| Diabetic nephropathy | 2 (6) | 12 (6) | |
| Polycystic kidney disease | 4 (11) | 36 (19) | |
| Hypertension/nephrosclerosis | 3 (8) | 18 (10) | |
| Other | 6 (16) | 34 (18) | |
| Duration of RRT (months) | 12 ± 16 | 20 ± 21 | .010 |
| Donor type (deceased) | 36 (97) | 174 (92) | .433 |
| Body mass index (kg/m2) | 28 ± 5 | 30 ± 6 | .340 |
| Diabetes | 11 (30) | 68 (36) | .589 |
| Hypertension | 37 (100) | 189 (100) | – |
| Cardiovascular disease | 12 (32) | 94 (50) | .080 |
| Chronic pulmonary disease | 4 (11) | 22 (12) | .891 |
| Estimated GFRa (ml/min) | 46 ± 17 | 51 ± 20 | .149 |
| Immunosuppression at vaccination | |||
| Tacrolimusb | 36 (97) | 159 (84) | .062 |
| Cyclosporine | 0 (0) | 25 (13) | .039 |
| Mycophenolate mofetil/sodium | 32 (86) | 168 (89) | .891 |
| Sirolimus | 1 (3) | 6 (3) | .713 |
| Depleting ALA within 6 monthsc | 2 (5) | 0 (0) | .024 |
Note: Data are number of patients (percentage) or mean ± SD.
Abbreviations: ALA, antilymphocyte antibody; COVID-19, coronavirus disease 2019; GFR, glomerular filtration rate; RRT, renal replacement therapy.
a
According to CKD-EPI formula.
b
Median tacrolimus trough levels were comparable in both groups (6.8 vs. 6.7 ng/ml, p = .767).
c
Thymoglobulin used for induction therapy in both patients.